Journal
ONCOGENE
Volume 25, Issue 11, Pages 1639-1648Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.onc.1209373
Keywords
GST; polymorphism; resistance; MAP kinase pathway
Funding
- NCI NIH HHS [R01 CA085660, CA53783] Funding Source: Medline
- NIEHS NIH HHS [T32 ES012878] Funding Source: Medline
Ask authors/readers for more resources
The super family of glutathione S-transferases (GSTs) is composed of multiple isozymes with significant evidence of functional polymorphic variation. Over the last three decades, data from cancer studies have linked aberrant expression of GST isozymes with the development and expression of resistance to a variety of chemicals, including cancer drugs. This review addresses how differences in the human GST isozyme expression patterns influence cancer susceptibility, prognosis and treatment. In addition to the well-characterized catalytic activity, recent evidence has shown that certain GST isozymes can regulate mitogen-activated protein kinases or can facilitate the addition of glutathione to cysteine residues in target proteins (S-glutathionylation). These multiple functionalities have contributed to the recent efforts to target GSTs with novel small molecule therapeutics. Presently, at least two drugs are in late-stage clinical testing. The evolving functions of GST and their divergent expression patterns in individuals make them an attractive target for drug discovery.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available